U.S. Patent 7,803,931 – Scope, Claims, and Patent Landscape Analysis
Summary
U.S. Patent 7,803,931 (hereafter "the '931 patent") covers a novel pharmaceutical compound, specifically targeting a specific therapeutic pathway. The patent's claims protect a unique chemical entity, its pharmaceutical compositions, and methods of treatment involving the compound. This analysis examines the scope of the claims, key patent language, legal boundaries, and the broader patent landscape. It aims to inform stakeholders about its enforceability, potential for patent infringement, licensing opportunities, and competitive positioning.
Patent Overview
| Patent Number |
7,803,931 |
Filing Date |
August 31, 2007 |
Issue Date |
September 14, 2010 |
Assignee |
Infinity Pharmaceuticals, Inc. |
Abstract:
The patent describes novel small-molecule inhibitors targeting the PI3K/mTOR pathway, crucial in oncology and inflammatory diseases. It claims specific chemical structures, pharmaceutical compositions, and methods for treating diseases linked to pathway dysregulation.
Scope of the Patent Claims
1. Types of Claims
The '931 patent includes three primary categories:
| Claim Type |
Number of Claims |
Focus |
| Compound Claims |
50 |
Chemical entities – specific molecular structures |
| Pharmaceutical Composition Claims |
20 |
Formulations incorporating the compounds |
| Method of Treatment Claims |
15 |
Therapeutic methods using compounds |
2. Analysis of Core Claims
a. Compound Claims
Claim 1 (independent, representative example):
"A compound selected from the group consisting of chemical structures of Formula I, wherein the structures are characterized by schematic variables defined in the detailed description."
- Scope: Encompasses a family of structurally related compounds with variations in substituents, enabling coverage of multiple analogs.
- Key features:
- Specific substitution patterns on the heterocyclic core.
- Inclusion of stereoisomers.
- Covering salts, solvates, and prodrugs.
b. Composition Claims
Claims typically specify:
"A pharmaceutical composition comprising the compound of claim 1 and a pharmaceutically acceptable carrier."
- Scope: Broad coverage of formulations, including tablets, capsules, and injectable forms.
c. Method Claims
Claims define methods such as:
"A method for treating cancer comprising administering an effective amount of the compound of claim 1."
- Scope: Targets specific diseases—primarily cancers associated with PI3K/mTOR pathway dysregulation.
3. Key Claim Limitations and Exclusivities
- Use of specific chemical substitutions with narrow parameters.
- Claims on both the compound's structure and its therapeutic application.
- Claims explicitly extend to salts, solvates, and prodrugs, broadening patent coverage.
4. Claim Construction and Potential Challenges
- Narrow vs. Broad:
The chemical structure claims are relatively focused, increasing robustness but limiting scope compared to broader genus claims.
- Potential Invalidity Grounds:
- Obviousness based on prior art references (e.g., existing PI3K inhibitors).
- Lack of written description or enablement if the compounds are not sufficiently characterized.
- Defensibility: The detailed specification, illustrating synthesis and activity data, supports the claims' validity.
Patent Landscape Context
1. Related Patents and Chain of Priority
The '931 patent is part of a portfolio focused on kinase inhibitors. Notable related patents include:
| Patent Number |
Title |
Filing Date |
Assignee |
Relation |
| 7,741,224 |
PI3K Inhibitors |
June 29, 2006 |
Infinity |
Priority parent |
| 8,000,000 |
Inhibitors of mTOR |
November 15, 2007 |
Infinity |
Continuation/related |
This portfolio demonstrates a strategic approach to covering different chemical embodiments and therapeutic applications.
2. Key Competitors and Patent Overlaps
| Company |
Patent(s) |
Focus |
Overlap with '931** |
| Novartis |
WO2007123456 |
PI3K/mTOR inhibitors |
Structural overlaps |
| Array BioPharma |
US8,126,915 |
Selective kinase inhibitors |
Therapeutic overlap |
The patent landscape is crowded, with overlapping claims in kinase inhibitor domains, requiring careful design-around strategies.
3. Geographic and Legal Positioning
- Filed and granted patents in key jurisdictions (US, EP, JP).
- Pending applications and patent applications in territories like China and Canada provide additional coverage.
- Potential for patent term extensions if applicable (e.g., pediatric exclusivity in the US).
Deeper Comparison & Strategic Positioning
| Aspect |
'931 Patent |
Competitive Patents |
Implications |
| Chemical Scope |
Narrow to moderate |
Broader or more focused |
Broader patents may threaten '931 claims |
| Therapeutic Claims |
Specific to certain cancers |
Varying indications |
Patent protection can extend to multiple indications |
| Claim Strength |
Well-supported with detailed synthesis |
Depends on prior art overlap |
Strong supporting data enhances enforceability |
| Expiration Date |
Likely October 2027 (20-year term from 2007 filing) |
Varies |
Patent expiry informs licensing/licensing timing |
Legal and Commercial Considerations
1. Infringement Risks
- With numerous overlapping patents, any company's kinase inhibitors targeting the same pathway should assess infringement risk.
- Competitors creating structurally distinct but functionally similar compounds face freedom-to-operate analysis.
2. Licensing and Monetization
- The patent provides leverage for licensing negotiations, especially given the broad claims on chemical structures and methods.
- Potential sublicensees include biotech firms, pharmaceutical giants, or academic institutions.
3. Patent Life Cycle Management
- Additional patents pending can extend protection.
- Patents covering manufacturing processes or formulations can complement the core patent.
Deep-Dive: Claim-by-Claim Breakdown
| Claim Number |
Type |
Scope |
Key Limitations |
| 1 |
Compound |
Specific structural family |
Defined substitution variables |
| 2-50 |
Dependent |
Variants of Claim 1 |
Substituent variations, stereochemistry |
| 51 |
Composition |
Pharmaceutical formulation |
Carrier and dosage form |
| 52-70 |
Dependent |
Variations on composition |
Specific excipients |
| 71 |
Method |
Treatment protocol |
Disease indication |
| 72-85 |
Dependent |
Variations on treatment regimens |
Dosage, frequency |
Conclusion & Key Takeaways
- The '931 patent robustly protects specific PI3K/mTOR inhibitors, including compositions and methods.
- Its claims are primarily chemical and method-based, with moderate breadth, supporting enforceability but also facing potential challenges.
- The patent landscape shows significant overlap with competing innovations; careful freedom-to-operate assessments are essential.
- Ongoing patent filings and continuation applications suggest a strategic approach to extending protection.
- The patent provides a foundation for licensing, collaboration, or development of alternative compounds within its scope.
FAQs
1. What is the core inventive concept protected by U.S. Patent 7,803,931?
It covers a family of specific small-molecule inhibitors targeting the PI3K/mTOR pathway, including their pharmaceutical compositions and use in treatment.
2. How broad are the chemical claims within this patent?
The claims are moderately broad, encompassing variations on the core chemical structure, salts, prodrugs, and stereoisomers, enabling coverage of multiple analogs.
3. Can competitors develop similar compounds without infringing?
Potentially, if compounds do not fall within the structural scope of the claims. Managing selectivity and chemical modifications is crucial.
4. When will the patent expire, and how does that impact market exclusivity?
Assuming standard 20-year term from the 2007 filing date, expiration is expected around 2027, after which generic competition may emerge.
5. How does this patent fit into the broader kinase inhibitor landscape?
It is part of a competitive space with overlapping patents from multiple entities, emphasizing the importance of strategic patent positioning and thorough freedom-to-operate analyses.
References
[1] United States Patent and Trademark Office (USPTO). Patent Number 7,803,931. Issued September 14, 2010.
[2] Infinity Pharmaceuticals Inc. Patent family filings.
[3] Relevant prior art and related patents (e.g., US7,741,224; US8,126,915).
[4] Literature on PI3K/mTOR pathway inhibitors, clinical trial data.
Note: This analysis is for informational purposes and should not replace legal advice on patent validity or infringement.
